Lv1
90 积分 2024-07-04 加入
Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial
12小时前
已完结
CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer
5个月前
已完结
[Expert consensus on Claudin18.2 expression testing in gastric cancer (2025 version)]
5个月前
已完结
皖公网安备34019202002308
